Related Experiment Video

Updated: Aug 9, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

10.2K

Minireview on current antiangiogenic agents in oncology and ophthalmology

M Cernak, L Nogova

    Neoplasma
    |August 20, 2015
    PubMed

    Insights

    Antiangiogenic drugs used for cancer treatment can cause eye side effects but may also treat existing ocular conditions. Close collaboration between oncologists and ophthalmologists is crucial for managing these patients.

    Area of Science:

    • Oncology and Ophthalmology
    • Pharmacology
    • Ocular Therapeutics

    Background:

    • Antiangiogenic drugs have been used for over a decade in various cancer treatments.
    • These agents are also approved for local ocular applications to treat conditions like macular degeneration and diabetic retinopathy.
    • The known activity of antiangiogenic agents in the eye prompted an investigation into their systemic effects.

    Purpose of the Study:

    • To review the current literature on ocular side effects of systemically administered antiangiogenic drugs in cancer patients.
    • To investigate whether systemic antiangiogenic therapy can concurrently treat ocular disorders in cancer patients.
    • To highlight the importance of multidisciplinary collaboration between oncologists and ophthalmologists.

    Main Methods:

    • Systematic literature review of published studies.
    • Analysis of data regarding ocular side effects and therapeutic effects of antiangiogenic drugs.
    • Focus on systemic application in cancer patients.

    Main Results:

    • Systemic antiangiogenic drugs can lead to ocular side effects in cancer patients.
    • In some cases, these drugs may offer a therapeutic benefit for concurrent ocular conditions.
    • Evidence suggests a dual role of antiangiogenic agents in the ocular system.

    Conclusions:

    • Systemic antiangiogenic therapy necessitates careful monitoring for ocular side effects.
    • Potential therapeutic benefits for ocular disorders should be considered.
    • Integrated care involving oncologists and ophthalmologists is essential for optimal patient management.

    More Related Videos

    Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

    Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

    Published on: December 5, 2020

    3.1K
    Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization05:14

    Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

    Published on: August 11, 2023

    1.7K

    Related Concept Videos

    Cancer Therapies02:49

    Cancer Therapies

    Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
    However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Mechanism of Angiogenesis01:10

    Mechanism of Angiogenesis

    Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
    Regulation of Angiogenesis and Blood Supply01:24

    Regulation of Angiogenesis and Blood Supply

    Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
    Open Angle Glaucoma: Treatment01:27

    Open Angle Glaucoma: Treatment

    In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
    Drugs such as carbonic anhydrase inhibitors, α2- and...
    Angle Closure Glaucoma: Treatment01:28

    Angle Closure Glaucoma: Treatment

    Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...